drug
paclitaxel albumin bound
Marketedupdated 6mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugpaclitaxel36 co-mentions · 27 sources
- drugSOR-00736 co-mentions · 27 sources
- tagAdCom28 co-mentions · 25 sources
- tagPMA Approval28 co-mentions · 25 sources
- company$BSXBOSTON SCIENTIFIC CORP5 co-mentions · 5 sources
- tagOncology3 co-mentions · 1 sources
- companyBaxter Healthcare Corp1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 109 investigational indications.
indications
investigational
NSCLCBreast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying paclitaxel albumin bound
- phase2An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
- phase2A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
- phase3Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- phase3Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
- phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- phase3A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 13, 2027
85 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jul 12, 2034patentUS 9511046*PED
- Jan 12, 2034method-of-use (U-1434)US 9511046
- Sep 4, 2032patentUS 9393318*PED
- Sep 4, 2032patentUS 9597409*PED
- Mar 4, 2032method-of-use (U-1290)US 9393318
- Mar 4, 2032method-of-use (U-1290)US 9597409
- Feb 13, 2027patentUS 8034375*PED85d
- Aug 21, 2026patentUS 7758891*PED
- Aug 21, 2026patentUS 8268348*PED
- Aug 21, 2026patentUS 9101543*PED
- Aug 13, 2026method-of-use (U-1290)US 8034375
- Feb 21, 2026method-of-use (U-1434)US 7758891
- Feb 21, 2026method-of-use (U-1290)US 8268348
- Feb 21, 2026method-of-use (U-1434)US 9101543
News(10)
- Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweightsFaeth Therapeutics’ endometrial cancer prospect has cleared the phase 2 efficacy bar, emboldening the biotech to forge ahead with efforts to establish the oral therapy in a field dominated by injec…fiercebiotech · 13d ago
- ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer raceIncyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.fiercebiotech · 25d ago
- Novocure hit by cyberattack exposing patient dataNovocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that unauthorized access to some of its information systems exposed patient and emp…fiercebiotech · 2mo ago
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.stat · 5mo ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 6mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 6mo ago
- Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 6mo ago
- Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.onclive · 6mo ago
- Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLLore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.onclive · 6mo ago
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 6mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that